Observation on the efficacy of comprehensive treatment of intravitreal injection of ranibizumab for macular edema

Objective To evaluate the clinical efficacy of intravitreal injection of ranibizumab combined with triamcinolone acetonide or retinal photocoagulation for the treatment of macular edema due to retinal vein occlusion (RVO). Methods The data of 97 eyes of 97 patients with RVO from Oct. 2017 to Apr. 2018 were analyzed retrospectively.There were 50 eyes of 50 patients with retinal branch vein occlusion (BRVO) and 47 eyes of 47 patients with central retinal vein occlusion (CRVO). The changes in visual acuity, FFA and central retinal thickness (CRT) before and after treatment were compared. The average follow-up time was 6 months. Results The preoperative visual acuity (LogMAR) of the BRVO group was 0.636±0.471, and the postoperative visual acuity was 0.368±0.235. The preoperative CRT was decreased from (443.48±156.23) μm to (220.21±20.31) μm. In the CRVO group, the preoperative visual acuity (LogMAR) was 0.861±0.531, the postoperative visual acuity was 0.522±0.443, and the preoperative CRT was (549.11±225.30) μm. After treatment, it decreased to (249.36±40.13) μm. Before and after treatment, the differences were statistically significant (P<0.05). No serious adverse reaction in the eyes or system occurred in either group. Conclusion Intravitreal injection of ranibizumab combined with triamcinolone acetonide or retinal photocoagulation for RVO can promote retinal edema regression and improve visual acuity. Key words: Photocoagulation, retina; Ranibizumab, intravitreal injection; Obstruction of veins, retina; Edema, macular